Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,932.38
(
0.80%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
96.37
(
-4.74%
)
Bitcoin
76,654.95
(
-0.80%
)
News Focus
News Focus
Post# of 12451
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

chris194

Send PM Follow Ignore
Followers 0
Posts 42
Boards Moderated 0
Alias Born 07/23/2013

chris194

Re: None

Tuesday, 08/02/2016 1:41:06 PM

Tuesday, August 02, 2016 1:41:06 PM

Post# of 12451
They should file three NDA's by the end of this year. They have committed to filing Rizaport US, Taladafil and the PAR 2 drug this year.Read the earnings call transcripts. It is vitally important that the company meet this timeline. They have a long history of letting everything slide.
At year end with one drug selling ( Forfivo) and one approved for Europe( rizaport ) and three NDA's filed, this will be way undervalued at current market cap. This is ignoring Suboxone, Loxapine, cough and cold and Montelukast.
The future is bright if they can execute.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today